Organization
New York Medical College
23 clinical trials
3 abstracts
Clinical trial
A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic SyndromeStatus: Completed, Estimated PCD: 2023-04-04
Abstract
Racial disparities among triple negative breast cancer clinical trial enrollees between 2010-2023.Org: New York Medical College, Valhalla, Nykode Therapeutics, Albert Einstein College of Medicine, Bronx, NY,
Abstract
Disparities in the initial presentation of melanoma across two socioeconomically diverse New York City neighborhoods.Org: Rutgers NJMS, NYU Langone Health, New York Medical College,
Abstract
Colorectal cancer and the heart: Uncovering the beat of racial disparities in MACCE.Org: Landmark Medical Center, New York Medical College, Department of Oncology, National Taiwan University Hospital, Mayo Clinic,
Clinical trial
Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure From Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults With LymphomaStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS MalignanciesStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Pilot Study to Determine the Safety of Defibrotide in Children With High Risk Kawasaki DiseaseStatus: Active (not recruiting), Estimated PCD: 2023-10-24
Clinical trial
The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic PurpuraStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase II Study to Determine the Safety of Defibrotide in Sickle Cell Disease-Related Acute Chest SyndromeStatus: Completed, Estimated PCD: 2022-07-01
Clinical trial
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients Following Ganciclovir Prophylaxis Until Day +100Status: Completed, Estimated PCD: 2021-12-15
Clinical trial
A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections With Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult RecipientsStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Pilot Study in the Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult RecipientsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Pilot Study of SARS-CoV-2 Specific Cytotoxic T Lymphocytes (SARS-CoV-2-CTLs) for Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2024-08-15
Clinical trial
Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease or Beta Thalassemia Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) AddbackStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHLStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult RecipientsStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult RecipientsStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of Chinese Herbal Therapy and Multiple Food Allergen Oral ImmunotherapyStatus: Completed, Estimated PCD: 2020-07-02
Clinical trial
Phase I Trial of Targeted Immunotherapy With Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults With High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART)Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
PROJECT PREVENT: Metronidazole Antibiotic Per Vagina Before Hysterectomy: Is Additional Antibiotic Prophylaxis Beneficial?Status: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients With Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated With Either Renal and/or Pulmonary Dysfunction With Either Refractory or Progressive Disease Following Defibrotide TherapyStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase II Open-Label Randomized Study of Anti-Viral Antibiotic Therapy With and Without Familial (Maternal) Cytomegalovirus (CMV) Cytotoxic T Lymphocytes (CTLs) in Neonates With Moderate/Severe Maternal Acquired CMV InfectionStatus: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)Status: Active (not recruiting), Estimated PCD: 2024-12-01